prothena.com (PRTA) Kompaniya qiymatining sof foydaga nisbati
Prothena Corporation (PRTA) neyronlar degeneratsiyasiga qarshi kurashishga e'tibor qaratadi, bunda har qanday muvaffaqiyatsiz dori sinovlari natijasi aktivlar qiymatining keskin pasayishiga olib kelishi mumkin. Shu bilan birga, Prothena Corporation suv iste'molini va laboratoriya chiqindilarini minimallashtirish uchun ongli ishlab chiqarish tamoyillarini joriy qilmoqda. Joriy ko'rsatkich -19.10 darajasida turibdi, GURU.Markets platformasidagi narxlar grafigi esa ulkan R&D xarajatlari va hamkorlar moliyalashtirishiga bog'liqlik natijasida yuzaga kelgan tebranishlarni aks ettirmoqda.
%20Narxning%20foydaga%20nisbati&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_PRTA_-_Prothena-Corporation_-_Price-to-Earnings-Ratio "Prothena Corporation PLC (PRTA): Kapitalizatsiyaning foydaga nisbati 04.07.2022dan 12.11.2026gacha | 👁️GURU.Markets👁️")
Prothena Corporation (PRTA) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- aksiya narxi va konsensus maqsadli narx:
- bozor kapitallashuvi tafsilotlari:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Barcha qarzlarning o‘z mablag‘lariga nisbati Prothena Corporation|PRTA - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati prothena.com|PRTA - Kompaniya qarzlari|Qarzning balans qiymatiga nisbati Prothena Corporation plc|PRTA - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli qarzlari Prothena|Oraliq qoplash koeffitsiyenti prothena.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
PRTA - Sof foyda|Kelajakdagi foyda Prothena Corporation|PRTA - Narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati Prothena Corporation PLC|PRTA - Narxning foydaga va o‘sish sur’atiga nisbati|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati Prothena Corporation plc|PRTA - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|So'nggi 12 oy davomida bitta aksiya uchun foyda Prothena|PRTA - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi o'n ikki oy davomida yillik hisobda bir aksiya uchun foyda o'sishi prothena.com|PRTA - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning kutilayotgan dinamikasi Prothena Corporation
Kompaniyaning har tomonlama tahlili:Prothena Corporation plc PRTA
P/E koeffitsiyenti foydaning bir birligining bozor qiymatini aks ettirib, biznesning o'sish sur'atlariga oid investorlar kutganlarini ifodalaydi. Ushbu koeffitsiyentni aktivlar sifati bilan solishtirish kompaniya qimmat baholangan yoki arzon baholanganini aniqlash imkonini beradi. P/E baholash tendentsiyalarini tahlil qilish orqali qat'iy pul-kredit siyosati sharoitida kapital siqilish darajasini aniqlash mumkin. Prothena Corporation (PRTA) uchun ushbu ko'rsatkich juda muhimdir, chunki u bozorning sinovlarning so'nggi bosqichidagi innovatsion antitelolarning tijorat muvaffaqiyatiga bo'lgan ishonchini aks ettiradi.
Muhim raqobatchilar
biogen.com - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati Neurocrine Biosciences, Inc. (NBIX)|RGC (Regencell Bioscience Ltd) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Axsome Therapeutics Inc AXSM|ACADIA Corp (ACAD) - Kapitalizatsiyaning foydaga nisbati|XENE: Narx-foyda koeffitsiyenti|vikingtherapeutics.com - Bozor narxining sof foydaga nisbati|SUPN: P/E multiplikatori|Catalyst Pharma - Kompaniya qiymatining sof foydaga nisbati|DNLI (Denali Therapeutics Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Harmony Corp HRMY|Narxning foydaga nisbati Biohaven Ltd. (BHVN)|amylyx.com - Narx-foyda multiplikatori|P/E multiplikatori TRVI (Trevi Therapeutics, Inc.)|P/E multiplikatori Praxis Precision Medicines Inc PRAX|AVXL: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati CBLL (CeriBell EEG)|ALEC: P/E multiplikatori|Narx-foyda koeffitsiyenti annexonbio.com|Narxning foydaga nisbati Omeros Corp|Kapitalizatsiyaning foydaga nisbati Neurogene Inc NGNE|Narxning foydaga nisbati AC Immune Corp (ACIU)|VYGR (Voyager Corp) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Neumora Therapeutics NMRA|SCLX (scilexholding.com) - Kapitalizatsiyaning sof foydaga nisbati|TVGN - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Alpha Cognition|Cognition Therapeutics, Inc. (CGTX) - Narxning foydaga nisbati|Inhibikase Pharma - Kompaniya qiymatining sof foydaga nisbati|SAVA (Cassava Sciences, Inc.) - P/E multiplikatori|P/E multiplikatori Assertio Therapeutics|Narx-foyda koeffitsiyenti COYA (Coya Therapeutics, Inc.)|Bozor narxining sof foydaga nisbati VTGN|P/E multiplikatori OVID (Ovid Therapeutics)|Biznesning o‘zini qoplash muddati Acumen Pharmaceuticals, Inc (ABOS)|CRVO - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Alterity Therapeutics|clene.com (CLNN) - Narxning foydaga nisbati|Narx-foyda multiplikatori PEPG|Narxning foydaga nisbati Jupiter Neurosciences|Relmada Corp - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati Annovis Bio, Inc. (ANVS)|GRCE (gracetx.com) - Kompaniya qiymatining sof foydaga nisbati|Firefly Neuroscience - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati KLTO (ANEW Medical)|NeuroSense Therapeutics, Ltd. - P/E multiplikatori|RVPH - P/E multiplikatori|metaviatx.com (MTVA) - Narxning foydaga nisbati|Narx-foyda multiplikatori NRXS|HSDT (Helius Medical Technologies, Inc.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Passage Bio Corp PASG|Narx-foyda koeffitsiyenti NEUP (Neuphoria Therapeutics Inc.)|P/E multiplikatori Minerva (NERV)|Narxning foydaga nisbati Athira Pharma, Inc. ATHA|Kompaniya qiymatining sof foydaga nisbati ADXN|ALZN - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Cyclerion Therapeutics|protagenic.com (PTIX) - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati KTTA (Pasithea Therapeutics Corp.)|Narxning foydaga nisbati Cortigent Inc|ATXI: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati BrainStorm Cell Therapeutics (BCLI)|CARA - Kapitalizatsiyaning foydaga nisbati|Chromocell Therapeutics Corporation - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati ELYM (Eliem Therapeutics, Inc.)|Intra-Cellular - P/E multiplikatori|Kompaniya qiymatining sof foydaga nisbati LBPH (longboardpharma.com)|MRNS: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati NKGen Biotech Inc (NKGN)|Narxning foydaga nisbati NeuroBo|Narx-foyda multiplikatori SAGE (Sage Therapeutics Inc)|P/E multiplikatori SNPX|P/E multiplikatori trevena.com (TRVN)|Vigil Neuroscience, Inc. - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati WENA|Cerevel - P/E multiplikatori
